Meinntech

Notice

Anyfusion ACPi system, Daegu K University Hospital and Italy G Company Milan University Hospital
Toxic strong anti-cancer drugs and contamination risk injections are dispensed by people (pharmacists or compounding professionals) in all countries with syringes on clean benches in sterile rooms wearing safety equipment. Drugs and liquids are dispensed by syringing from a vial or bottle anti-cancer or injectable drug container under vacuum into an extraction dispensing container. During the extraction and introduction process, it is difficult to extract and introduce quantitatively and accurately with negative and positive pressure, requiring repetition and skill, but it is a 3D work that is most avoided by young pharmacists due to the risk of lung damage, carcinogenesis, and skin necrosis by inhaling vapoured oil caused by exposure and leakage. To facilitate extraction and prevent exposure and leakage, 28 developed countries use expensive CSTDs, and it is a 6 trillion won market. Some large hospitals have introduced dispensing robots, but low cost-effectiveness and high maintenance costs are problems. Recently, domestic and foreign medical device companies provided samples saying that CSTD will soon be calculated separately (salary). It was possible to compare the CSTD function with the Anyfusion ACPi system, which does not use a syringe, minimises exposure and leakage, and dispenses by automatically extracting and introducing the correct amount of medicine. The advantages of Anyfusion ACPi system such as multi-purpose dispensing, universality, cost-effectiveness, and salary were identified at Daegu K University Hospital compared to Anyfusion ACPi system, which accurately and simultaneously automatically introduces and dispenses anti-cancer drugs and solution quantities into PCA balloons, which is impossible with CSTD and difficult with syringes, and is more complete than CSTD with MCST and CAM, and was asked to provide information to submit a formal demo application. As the Anyfusion ACPi system is the world's first, it was developed by a small company with no name, and it was not easy to adapt and apply due to reliability issues due to lack of clinical evidence, and it was rejected due to a perception crisis as a factor hindering the introduction of pharmacy robots. The FDA STeP selection seems to have a decisive impact. Depending on the outcome, the ripple effect on domestic hospitals is large, and hospital costs are also reduced by being paid by infusion, so explosive demand is expected. It is expected to be used in all domestic hospitals as early as next year. Company G, claiming exclusivity in Italy and Europe, is travelling to a hospital in Milan, Italy in early May for a demonstration. It is expected that hospitals around the world using CSTDs will be equally compared and eventually CSTDs will disappear. The Anyfusion cylinder pump was recommended by a professor at Seoul National University's Department of Biomedical Engineering who tested it for the purpose of infusing anti-cancer drugs. The Anyfusion ACPi system will be injected with the Anyfusion cylinder pump from dispensing to injection, and the demand for the pump will expand to the entire hospital once the safety and efficacy comparisons guaranteed by the FDA are verified, as cancer patients' chemotherapy injections require accuracy, just like in the NICU. Ultimately, the infusion pump market and the dispensing market will undergo a paradigm shift to Anyfuion. When a premature baby was recently admitted to the NICU at Ewha Womans Hospital, and medicines were injected with a conventional pump, the levels of blood sugar and electrolytes were unstable, and normal growth and development could not be expected. A professor who knew Anyfusion informed me that the aberration came to normal immediately after SOS and urgent infusion, and the child was treated and grew healthily for about a month. It is very rewarding to know that Anyfusion played a role in helping a child grow up healthy. The professor's urgent purchase request was delivered, and I can still see the bright faces of the nurses and purchasing staff who used it. It's all thanks to you. Thank you.

Anyfusion ACPi system, Daegu K University Hospital and Italy G Company Milan University Hospital

Toxic strong anti-cancer drugs and contamination risk injections are dispensed by people (pharmacists or compounding professionals) in all countries with syringes on clean benches in sterile rooms wearing safety equipment. Drugs and liquids are dispensed by syringing from a vial or bottle anti-cancer or injectable drug container under vacuum into an extraction dispensing container. During the extraction and introduction process, it is difficult to extract and introduce quantitatively and accurately with negative and positive pressure, requiring repetition and skill, but it is a 3D work that is most avoided by young pharmacists due to the risk of lung damage, carcinogenesis, and skin necrosis by inhaling vapoured oil caused by exposure and leakage.

To facilitate extraction and prevent exposure and leakage, 28 developed countries use expensive CSTDs, and it is a 6 trillion won market. Some large hospitals have introduced dispensing robots, but low cost-effectiveness and high maintenance costs are problems. Recently, domestic and foreign medical device companies provided samples saying that CSTD will soon be calculated separately (salary). It was possible to compare the CSTD function with the Anyfusion ACPi system, which does not use a syringe, minimises exposure and leakage, and dispenses by automatically extracting and introducing the correct amount of medicine. The advantages of Anyfusion ACPi system such as multi-purpose dispensing, universality, cost-effectiveness, and salary were identified at Daegu K University Hospital compared to Anyfusion ACPi system, which accurately and simultaneously automatically introduces and dispenses anti-cancer drugs and solution quantities into PCA balloons, which is impossible with CSTD and difficult with syringes, and is more complete than CSTD with MCST and CAM, and was asked to provide information to submit a formal demo application.
As the Anyfusion ACPi system is the world's first, it was developed by a small company with no name, and it was not easy to adapt and apply due to reliability issues due to lack of clinical evidence, and it was rejected due to a perception crisis as a factor hindering the introduction of pharmacy robots. The FDA STeP selection seems to have a decisive impact. Depending on the outcome, the ripple effect on domestic hospitals is large, and hospital costs are also reduced by being paid by infusion, so explosive demand is expected. It is expected to be used in all domestic hospitals as early as next year.
Company G, claiming exclusivity in Italy and Europe, is travelling to a hospital in Milan, Italy in early May for a demonstration. It is expected that hospitals around the world using CSTDs will be equally compared and eventually CSTDs will disappear. The Anyfusion cylinder pump was recommended by a professor at Seoul National University's Department of Biomedical Engineering who tested it for the purpose of infusing anti-cancer drugs. The Anyfusion ACPi system will be injected with the Anyfusion cylinder pump from dispensing to injection, and the demand for the pump will expand to the entire hospital once the safety and efficacy comparisons guaranteed by the FDA are verified, as cancer patients' chemotherapy injections require accuracy, just like in the NICU. Ultimately, the infusion pump market and the dispensing market will undergo a paradigm shift to Anyfuion.
When a premature baby was recently admitted to the NICU at Ewha Womans Hospital, and medicines were injected with a conventional pump, the levels of blood sugar and electrolytes were unstable, and normal growth and development could not be expected. A professor who knew Anyfusion informed me that the aberration came to normal immediately after SOS and urgent infusion, and the child was treated and grew healthily for about a month. It is very rewarding to know that Anyfusion played a role in helping a child grow up healthy. The professor's urgent purchase request was delivered, and I can still see the bright faces of the nurses and purchasing staff who used it. It's all thanks to you.

Thank you.

Next	Status of Overseas and Domestic sales
Prev	Selected as a recommended target for the 2023 excellent R&D innovative product designation system